Sign In
Buy RHHBY
$49.06
-0.130 (-0.264%)
At Close: Jun 03, 2026
The new cobas® 6800/8800 Systems version 2.0 and software version 2.0.1 enhances throughput, run flexibility, enables sample prioritization and is available as an upgrade to existing systems. Laborat
Roche Holding AG (RHHBY) Shareholder/Analyst Call Transcript
09:12pm, Thursday, 11'th Dec 2025
Roche Holding AG (RHHBY) Shareholder/Analyst Call Transcript
Roche's Breast Cancer Drug Cuts Risk of Death by 30% in Phase III
11:31am, Thursday, 11'th Dec 2025
RHHBY's giredestrant cuts the risk of invasive disease recurrence or death by 30% in phase III, fueling momentum for a next-generation endocrine therapy.
Basel, 11 December 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has secured CE Mark approval for its mass spectrometry reagent pack for antibiotics drug monitoring. This establish
Market Today: Fed Cut; Oracle, Rivian, Amazon in Focus
05:34pm, Wednesday, 10'th Dec 2025
Guru Stock PicksPaul Tudor Jones has made the following transactions:Reduce in DOMO by 74.59%Sold out in ITAdd in BRY by 6686.5%New position in LDOSStock News F
Patients as Partners® in Clinical Research Now Part of Questex's Fierce Life Sciences Portfolio; First Conference to Put Patients at the Same Level as R&D Executives in a National Event Takes Place i
Roche Says Breast-Cancer Drug Shows Potential to Become Standard-Of-Care
09:20am, Wednesday, 10'th Dec 2025
Giredestrant lowered the risk of disease recurrence or death by 30%, compared with standard-of-care endocrine therapy, according to the company.
Genentech's Giredestrant Reduced Risk of Invasive Disease Recurrence or Death by 30% in ER-positive Early-Stage Breast Cancer
08:20am, Wednesday, 10'th Dec 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive data from the Phase III lidERA Breast Cancer study evaluatin
Roche breast cancer pill cuts risk of disease recurrence by 30% in trial
08:16am, Wednesday, 10'th Dec 2025
Roche said on Wednesday its experimental oral drug giredestrant reduced the risk of breast cancer recurrence by 30% compared with standard endocrine therapy, in what it said marked the first big advan
Roche's giredestrant reduced risk of invasive disease recurrence or death by 30% in ER-positive early-stage breast cancer
08:15am, Wednesday, 10'th Dec 2025
Basel, 10 December 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive data from the phase III lidERA Breast Cancer study evaluating investigational giredestrant as an adjuvant endocrin
First Look: Fed Cut Looms; SpaceX IPO; J&J Myeloma Data; Google Probe
07:37am, Wednesday, 10'th Dec 2025
Stock News Fed set for a âhawkish cutâ: The Federal Reserve is widely expected to deliver a third 25 bp rate cut amid sharp divisions over inflation vs. job
Market Today: Fed Cut Looms, Nvidia's China Shift, Target's SoHo Push, OpenAI Taps Slack CEO
05:34pm, Tuesday, 09'th Dec 2025
Stock News Fed set for âhawkish cut': Goldman Sachs (GS) and other Wall Street desks expect the Federal Reserve to deliver a third straight 25 bps rate cut wh
First Look: Paramount's WBD bid, IBM-Confluent, Boeing-Spirit
07:37am, Tuesday, 09'th Dec 2025
Stock News Paramount goes hostile for WBD: Paramount Skydance (PSKY) launched a hostile, all-cash $30-per-share offer for Warner Bros. Discovery (WBD), valuing
Roche launches new PCR test to help improve diagnostic accuracy for women affected by vaginitis in countries following the CE Mark
01:10am, Tuesday, 09'th Dec 2025
Basel, 9 December 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the CE Mark for its cobas® BV/CV (Bacterial Vaginosis/Candida Vaginitis) assay to accurately identify specific bacteria and
European Commission approves Roche's Gazyva/Gazyvaro for adults with active lupus nephritis
01:00am, Tuesday, 09'th Dec 2025
Basel, 9 December 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has approved Gazyva®/Gazyvaro® (obinutuzumab) in combination with mycophenolate mofetil (MMF)
